Evidence map›Paper›PMID 32522275›Full record

ArticleBMC cancer2020

Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.

Po-Jui Chen, Wing-Keen Yap, Yu-Chuan Chang, Chen-Kan Tseng, Yin-Kai Chao, Jason Chia-Hsun Hsieh, Ping-Ching Pai, Ching-Hsin Lee, Chan-Keng Yang, Albert Tsung-Ying Ho and 1 more

Abstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. The prognostic value of pretreatment [European radiology · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Po-Jui ChenDepartment of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan, Taiwan.
Wing-Keen YapDepartment of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan, Taiwan.
Yu-Chuan ChangDepartment of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chen-Kan TsengDepartment of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan, Taiwan.
Yin-Kai ChaoDivision of Thoracic Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Jason Chia-Hsun HsiehDivision of Medical Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Ping-Ching PaiDepartment of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan, Taiwan.
Ching-Hsin LeeDepartment of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan, Taiwan.
Chan-Keng YangDivision of Medical Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Albert Tsung-Ying HoDepartment of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Tsung-Min HungDepartment of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan, Taiwan. min7363@gmail.com.ORCID http://orcid.org/0000-0002-7736-0376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnresectable esophageal cancer harbors high mortality despite chemoradiotherapy. Better patient selection for more personalized management may result in better treatment outcomes. We presume the ratio of maximum standardized uptake value (SUV) of metastatic lymph nodes to primary tumor (NTR) in 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT) may provide prognostic information and further stratification of these patients.

methodsThe patients with non-metastatic and unresectable esophageal squamous cell carcinoma (SCC) receiving FDG PET/CT staging and treated by chemoradiotherapy were retrospectively reviewed. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cut-off value for NTR. Kaplan-Meier method and Cox regression model were used for survival analyses and multivariable analyses, respectively.

resultsFrom 2010 to 2016, 96 eligible patients were analyzed. The median follow-up time was 10.2 months (range 1.6 to 83.6 months). Using ROC analysis, the best NTR cut-off value was 0.46 for prediction of distant metastasis. The median distant metastasis-free survival (DMFS) was significantly lower in the high-NTR group (9.5 vs. 22.2 months, p = 0.002) and median overall survival (OS) (9.5 vs. 11.6 months, p = 0.013) was also significantly worse. Multivariable analysis revealed that NTR was an independent prognostic factor for DMFS (hazard ratio [HR] 1.81, p = 0.023) and OS (HR 1.77, p = 0.014).

conclusionsHigh pretreatment NTR predicts worse treatment outcomes and could be an easy-to-use and helpful prognostic factor to provide more personalized treatment for patients with non-metastatic and unresectable esophageal SCC.

Indexed as

Positron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveChemoradiotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleFluorodeoxyglucose F18HumansKaplan-Meier EstimateLymph NodesMaleMiddle AgedPrognosisProportional Hazards ModelsRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG PET)Distant metastasisEsophageal cancerMaximum standardized uptake value (SUV)Node-to-tumor SUV ratio (NTR)Personalized treatmentPrognosisRatioSquamous cell carcinoma (SCC)Unresectable

Identifiers

PMID32522275
PMCPMC7288503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.